Font A
*, Mellado B
*, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González del Alba A, Pinto A, Morales-Barrera R, Rodríguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX
*.
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer 2024; 130(3): 434-441.